120.83USD+0.35%Mkt Cap: —P/E: 132.581d ago
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value12.83B $
Revenue (TTM)830.81M $
Gross Profit816.73M $
Net Income (TTM)54.27M $
Revenue/Share7.968 USD
Last Price120.83 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees730
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)132.58
P/E (Forward)—
PEG—
EV/EBITDA1586.52
EV/Revenue15.44
P/S—
P/B18.34
EPS (TTM)0.91
EPS (Forward)—
52W Range
115.1998% of range120.94
52W High120.94 USD
52W Low115.19 USD
Profitability
Gross Margin98.30%
Oper. Margin16.12%
EBITDA Margin0.97%
Profit Margin6.64%
ROE8.23%
ROA0.47%
Growth
Revenue Growth31.70%
Earnings Growth24.10%
Cash Flow & Leverage
Operating CF109.70M $
CapEx (TTM)—
FCF Margin9.32%
FCF Yield—
Net Debt-298.78M $
Net Debt/EBITDA-36.96
Balance Sheet
Debt/Equity1.33
Current Ratio2.86
Quick Ratio2.50
Book Value/Sh6.540 USD
Cash/Share2.851 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.115.47M
Float96.36M
Insiders11.45%
Institutions76.92%
Technical
SMA 5023.44 (+415.4%)
SMA 20026.00 (+364.7%)
Beta0.46
S&P 52W Chg18.16%
Avg Vol (30d)637
Avg Vol (10d)705
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—